IMM 6.25% 30.0¢ immutep limited

martin rogers says cvac rights 100% prr

  1. 2,649 Posts.
    lightbulb Created with Sketch. 249
    Martin Rogers, Director PRR, was kind enough to reply on Sunday to an email from me yesterday, (which I read today after work) and to reply again tonight giving his permission for me to post it here. (Seemed unethical not to ask first)

    He asked me to include a note that the information is from previous 2007 disclosed information (apart from his comment about the current USA trip, of course).

    I contacted him to try to dispel some uncertainty I had about the Biomira rights and PRR's rights to CVAC and he has done so most satisfactorily. Maybe other already knew these facts, but I did not. He also volunteered some comment on the IP coverage and a positive comment about the current US trip.

    This was his full reply:

    "Biomira don't exist as a company anymore and the rights have been sold to Merck Sharpe & Dome.

    However, Prima collapsed its relationship with Biomira swapping project ownership for shares in Prima and Prima acquired the worldwide rights for Biomira. This is a very good position for shareholders. Prima owns 100% of CVac. Biomira sold their shares a while back.

    It is complex but the patents of Prima articulate the fusion of mucin-1(antigen) and mannan(carbohydrate adjunvant) to the dendritic cells presenting themselves to the immune system. This is a strong IP position to be in.

    Currently I just arrived in the US, things are very positive and we should be going through a great process for shareholders over the next 18 months."

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
-0.020(6.25%)
Mkt cap ! $435.7M
Open High Low Value Volume
31.5¢ 31.5¢ 29.5¢ $2.355M 7.796M

Buyers (Bids)

No. Vol. Price($)
8 128197 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 100000 1
View Market Depth
Last trade - 16.10pm 16/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.